Patents by Inventor Edward Robert Appelbaum

Edward Robert Appelbaum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 7982005
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: July 19, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • RECOMBINANT IL-5 ANTAGONISTS USEFUL IN TREATMENT OF IL-5 MEDIATED DISORDERS
    Publication number: 20100316634
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Application
    Filed: March 1, 2010
    Publication date: December 16, 2010
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • RECOMBINANT IL-5 ANTAGONISTS USEFUL IN TREATMENT OF IL-5 MEDIATED DISORDERS
    Publication number: 20090017020
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Application
    Filed: June 6, 2008
    Publication date: January 15, 2009
    Inventors: Robert S. AMES, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 7399837
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: July 15, 2008
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham P.L.C.
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 6946130
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: September 20, 2005
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Publication number: 20040156850
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Application
    Filed: November 4, 2003
    Publication date: August 12, 2004
    Applicants: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Publication number: 20030059429
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Application
    Filed: May 13, 2002
    Publication date: March 27, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 6129913
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: October 10, 2000
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 5851525
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: September 30, 1997
    Date of Patent: December 22, 1998
    Assignee: SmithKline Beecham Corporation
    Inventors: Robert S. Ames, Jr., Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Method for treatment and diagnosis of IL-5 mediated disorders
    Patent number: 5783184
    Abstract: The present invention relates to treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs and other altered antibodies such as Fabs, chimeric, human and humanized antibodies that do not block binding of human IL-5 to the .alpha.-chain of the human IL-5 receptor.
    Type: Grant
    Filed: June 21, 1996
    Date of Patent: July 21, 1998
    Assignee: SmithKline Beecham Corporation
    Inventors: Edward Robert Appelbaum, Richard Murray Cook
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 5693323
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 2, 1997
    Assignee: SmithKline Beecham Corporation
    Inventors: Robert S. Ames, Jr., Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 5683892
    Abstract: DNA encoding chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 4, 1997
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert S. Ames, Jr., Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen